Oxidative stress in uremia

Current Opinion in Nephrology and Hypertension

Volumn 12, Issue 6, 2003, Pages 593-598

  Himmelfarb, Jonathan ^a   Hakim, Raymond M ^b  

^a MAINE MEDICAL CENTER   (United States)

^b Renal Care Group   (United States)

Author keywords

Hemodialysis; Inflammation; Malnutrition; Oxidative stress; Uremia

Indexed keywords

ALDEHYDE; AMINO ACID; ANTIOXIDANT; ARACHIDONIC ACID DERIVATIVE; BIOLOGICAL MARKER; CARBOHYDRATE; DNA; ETHANE; LIPID; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN;

ANEMIA; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; IN VIVO STUDY; LIPID PEROXIDATION; MALNUTRITION; OXIDATIVE STRESS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; TREATMENT INDICATION; UREMIA;

HUMANS; KIDNEY FAILURE, CHRONIC; OXIDATIVE STRESS; PREVALENCE; UREMIA;

EID: 0442292075     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200311000-00004     Document Type: Review

References (45)

1. Foley R, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32(5 suppl 3):S112-S119.
2. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000; 356:147-152.
3. Becker BN, Himmelfarb J, Henrich WL, Hakim RM. Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 1997; 8:475-486.
4. Himmelfarb J, Ikizler TA, Stenvinkel P, Hakim RM. The elephant in uremia: reflections on oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62:1524-1538. An up-to-date review of the hypothesis that oxidative stress in uremia contributes to cardiovascular disease.
5. Marnett LJ, Riggins JN, West JD. Endogenous generation of reactive oxidants and electrophiles and their reactions with DNA and protein. J Clin Invest 2003; 111:583-593.
6. Papa S, Skulachev VP. Reactive oxygen species, mitochondria, apoptosis, and aging. Mol Cell Biochem 1997; 174:305-319.
7. Babior BM. The NADPH oxidase of endothelial cells. IUBMB Life 2000; 50:267-269.
8. Babior BM. The respiratory burst oxidase. Adv Enzymol Relat Areas Mol Biol 1992; 65:49-95.
9. Winterbourn CC, Vissers MC, Kettle AJ. Myeloperoxidase. Curr Opin Hematol 2000; 7:53-58.
10. Koppenol WH, Moreno JJ, Pryor WA, et al. Peroxynitrite, a cloaked oxidant formed by nitric oxide and superoxide. Chem Res Toxicol 1992; 5:834-842.
11. Eiserich JP, Hristova M, Cross CE, et al. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 1998; 391:393-397.
12. Heitzer T, Schlinzig T, Krohn K, et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104:2673-2678. This prospective study identifies oxidative stress biomarkers as being predictive of endothelial dysfunction and the risk of subsequent cardiovascular events in a population of patients with atherosclerotic coronary vascular disease.
13. Maggi E, Bellazzi R, Falaschi F, et al. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis? Kidney Int 1994; 45:876-883.
14. Uchida K. Role of reactive aldehyde in cardiovascular diseases. Free Rad Biol Med 2000; 28:1685-1696.
15. Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW. Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremice complications. Kidney Int 1999; 55:389-399.
16. Himmelfarb J, McMonagle E, McMenamin E. Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int 2000; 58:2571-2578.
17. Deneke SM. Thiol-based antioxidants. Curr Top Cell Regul 2000; 36:151-180.
18. Schafer FQ, Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Rad Biol Med 2001; 30:1191-1212.
19. Ueland PM, Mansoor MA, Guttormsen AB, et al. Reduced, oxidized and protein-bound forms of homocysteine and other aminothiols in plasma comprise the redox thiol status - a possible element of the extracellular antioxidant defense system. J Nutr 1996; 126(4 Suppl):1281S-1284S.
20. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, et al. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radl Biol Med 1996; 21:845-853.
21. Bostom AG, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology and potential relationship to arteriosclerotic outcomes. Kidney Int 1997; 52:10-20.
22. 2-like compounds are produced in vivo by humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A 1990; 87:9383-9387.
23. 2-isoprostanes in patients on long-term hemodialysis. Kidney Int 2001; 51:1960-1966.
24. 2 isoprostane levels are elevated in chronic hemodialysis patients. Clin Nephrol 2002; 88:190-197.
25. Salomon RG, Batyreva E, Kaur K, et al. Isolevuglandin-protein adducts in humans: products of free radical-induced lipid oxidation through the isoprostane pathway. Biochim Biophys Acta 2000; 1485:225-235.
26. Handelman GJ, Rosales LM, Barbato D, et al. Breath ethane in dialysis patients and control subjects. Free Rad Biol Med 2003; 35:17-23.
27. Ziouzenkova O, Asatryan L, Akmal M, et al. Oxidative cross-linking of ApoB100 and hemoglobin results in low density lipoprotein modification in blood. J Biol Chem 1999; 274:18916-18924.
28. Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003; 107:87-92.
29. Mezzano D, Pais EO, Aranda E, et al. Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 2001; 60:1844-1850.
30. Witko-Sarsat V, Friedlander M, Nguyen-Khoa T, et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161:2524-2532.
31. Annuk M, Zilmer M, Lind L, et al. Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol 2001; 12:2747-2752.
32. Stenvinkel P, Heimburger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 51:1899-1911.
33. Kato A, Odamaki M, Takita T, et al. Association between interleukin-6 and carotid atherosclerosis in hemodialysis patients. Kidney Int 2002; 61:1143-1152.
34. Stenvinkel P, Heimburger O, Jogestrand T. Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: association with Chlamydia pneumoniae seropositivity. Am J Kidney Dis 2002; 39:274-282.
35. Pecoits-Filho R, Bárány P, Lindholm B, et al. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002; 17:1684-1688.
36. Nguyen-Khoa T, Massy ZA, Pascal De Bandt J, et al. Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 2001; 16:335-340.
37. Danielski M, Ikizler TA, McMonagle E, et al. Linkage of hypoalbuminemia, inflammation, and oxidative stress in patients receiving maintenance hemodialysis therapy. Kidney Int 2003; 42(2):286-294
38. Halliwell B, Gutteridge JMC. The antioxidants of human extracellular fluids. Arch Biochem Biophys 1990; 280:1-8.
39. Halliwell B. Albumin - an important extracellular antioxidant? Biochem Pharmacol 1998; 37:569-571.
40. Stenvinkel P, Holmberg I, Heimburger O, Diczfalusy U. A study of plasmalogen as an index of oxidative stress in patients with chronic renal failure: evidence of increased oxidative stress in malnourished patients. Nephrol Dial Transplant 1998; 13:2594-2600.
41. Feldman HI, Santanna J, Guo W, et al. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 2002; 13:734-744.
42. Drueke T, Witko-Sarsat V, Massy Z, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002; 106:2212-2217. This paper demonstrates an association between the administration of intravenous iron, the development of advanced oxidation protein products as a biomarker of increased oxidative stress, and atherosclerosis as measured by carotid artery intima media thickness in dialysis patients.
43. Tovbin D, Mazor D, Vorobiov M, et al. Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation. Am J Kidney Dis 2002; 40:1005-1012.
44. Boaz M, Smetana S, Weinstein T, et al. Secondary Prevention with Antioxidants of Cardiovascular Disease in Endstage Renal Disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356:1213-1218.
45. Tepel M, van der Giet M, Statz M, et al. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a controlled trial. Circulation 2003; 107:992-995. This randomized controlled trial of the thiol-containing antioxidant N-acetylcysteine demonstrated a reduction in cardiovascular events in the treated group compared with the placebo group for primary prevention in hemodialysis patients.